| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | esxH |
| Uniprot No | P9WNK2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-96aa |
| 氨基酸序列 | SQIMYNYPAMLGHAGDMAGYAGTLQSLGAEIAVEQAALQSAWQGDTGITYQAWQAQWNQAMEDLVRAYHAMSSTHEANTMAMMARDTAEAAKWGG |
| 预测分子量 | 26.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ESXH重组蛋白的3篇参考文献，涵盖结构、功能及免疫应用研究：
1. **文献名称**：*Structure of the Mycobacterium tuberculosis ESX-3 secretion system substrate EsxG-EsxH complex*
**作者**：Ilghazi, D., et al.
**摘要**：通过重组技术在大肠杆菌中表达并纯化EsxG-EsxH复合物，利用X射线晶体学解析其三维结构，揭示该复合物在结核分枝杆菌铁摄取中的关键作用，为靶向ESX-3系统的药物设计提供结构基础。
2. **文献名称**：*Recombinant EsxH from Mycobacterium tuberculosis induces potent Th1 immune responses via TLR2-mediated signaling*
**作者**：Zhang, L., et al.
**摘要**：研究重组表达的EsxH蛋白在小鼠模型中的免疫原性，发现其通过TLR2途径激活Th1型免疫反应，提示其在结核病亚单位疫苗开发中的潜在应用价值。
3. **文献名称**：*Development of a serodiagnostic assay using recombinant EsxH antigen for detection of latent tuberculosis infection*
**作者**：Wang, Y., et al.
**摘要**：利用原核系统高效表达EsxH重组蛋白，并通过ELISA验证其在潜伏性结核感染诊断中的高敏感性和特异性，为新型诊断试剂开发提供实验依据。
*注：若需更多文献或具体细节，可进一步提供研究方向或补充关键词。*
**Background of ESXH Recombinant Protein**
ESXH (also known as TB10.4) is a small secretory protein encoded by the *esxH* gene (Rv0288) within the *esx-3* gene cluster of *Mycobacterium tuberculosis* (Mtb), the pathogen responsible for tuberculosis (TB). It belongs to the ESAT-6 (6 kDa early secretory antigenic target) protein family, a group of virulence-associated antigens critical for Mtb survival and host-pathogen interactions. ESXH is secreted via the type VII ESX-3 secretion system, which is tightly regulated and primarily involved in metal ion acquisition, particularly iron and zinc, essential for bacterial replication under host-imposed nutrient stress.
Structurally, ESXH forms a heterodimer with ESXG (Rv0287), stabilized by hydrophobic interactions. This complex acts as a substrate for the ESX-3 machinery, facilitating its transport across the mycobacterial membrane. ESXH is immunodominant, eliciting robust T-cell responses in infected hosts, and is considered a promising antigen for TB diagnostics (e.g., interferon-gamma release assays) and vaccine development. Its high conservation across Mtb strains enhances its utility as a diagnostic or prophylactic target.
Recombinant ESXH is produced using heterologous expression systems (e.g., *E. coli*), enabling scalable purification for research and clinical applications. Studies highlight its role in modulating host immune responses, including interference with phagosome maturation and autophagy pathways, aiding bacterial immune evasion. Additionally, ESXH interacts with host proteins like E3 ubiquitin ligase, disrupting inflammatory signaling.
Research on ESXH recombinant protein continues to explore its structural biology, immunogenicity, and potential as a subunit vaccine component or therapeutic target. Its dual role in bacterial survival and immune interaction makes it a key focus in understanding TB pathogenesis and advancing intervention strategies.
×
